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Introduction
Human immunodeficiency virus (HIV) has 
been known as a pandemic disease since 
its first discovery. At the end of 2017, there 
were 36.9 million individuals infected by HIV 
globally. Among them, 1.8 million cases were 
a new infections. It also found that there were 
940.000 cases of acquired immune deficiency 
syndrome (AIDS)-related death.1 In Indonesia1, 
there is an increase in a number of people 
living with HIV (PLHIV) and the number of 
AIDS-related death cases. The number of 
PLHIV increased from 610.000 in 2015 to 
630.000 in 2017. The number of AIDS-related 
death is also increased from 37.000 in 2015 
and 39.000 in 2017.1
HIV targets on a cluster of differentiation 4 
(CD4) cells (T helper cells) of its host. This leads 
to progressive deterioration of hosts’ immune 
systems and causes immunodeficiency in HIV-
infected patients. The HIV-infected patients 
could progress into AIDS. This phase is 
identified when the CD4 count has reached 
<200/μl or when the individual develops 
one or more opportunistic infections.2 HIV 
is treated with highly active antiretroviral 
therapy (HAART) which is a combination of 
antiretroviral (ARV).3 Opportunistic infections 
(OIs) are an infection that emerges due to 
a weakened immune systems and are often 
found in HIV patients. In HIV-infected patients, 
OIs could be life-threatening and are the 
major cause of AIDS-related death.2 Patients 
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Abstract
Background: Adverse cutaneous drug reactions (ACDRs) are common problems in patients during the 
treatment of various diseases. The clinical feature varies from mild manifestation such as morbilliform, 
urticaria, and contact dermatitis, to severe manifestation such as Stevens-Johnson syndrome (SJS) and 
Toxic Epidermal Necrolysis (TEN). Patients infected with the human immunodeficiency virus (HIV) 
have an increased risk of developing ACDRs due to immune system disruption. This study aimed to 
describe the clinical features of ACDRs in HIV patients and the drugs that cause ACDRs.
Methods: This study was a retrospective study using secondary data from medical records of HIV 
patients with ACDRs who visited Teratai Clinic of Dr. Hasan Sadikin General Hospital Bandung from 
2014 to 2018. Total sampling was applied and results were presented in percentage.
Results: There were 94 HIV patients with ACDRs out of 557 HIV patients. Adverse cutaneous drug 
reactions are commonly found in males aged 20–39 years old. The clinical features found were 
morbilliform (85.6%), SJS (8.9%), urticaria (4.4%), and erythroderma (1.1%). The most common 
drugs causing ACDRs were Cotrimoxazole (30%), Efavirenz (28.9%), and Nevirapine (16.7%).
Conclusions: The prevalence of ACDRs in HIV patients in this study is 16.9%. The most common 
clinical features are morbilli form and SJS with Cotrimoxazole, Efavirenz, and Nevirapine causing most 
of the ACDRs.
Keywords: Adverse cutaneous drug reactions, antiretroviral, drug hypersensitivity
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with AIDS are required to take OIs drugs 
and ARV. The use of several medications and 
dysregulation of the immune system could 
induce adverse drug reactions and drug 
interactions.4,5
Adverse cutaneous drug reactions (ACDRs) 
are rash found in a layer of skin and mucosa 
that emerges due to hypersensitivity reaction 
towards drugs. Drug eruption rates varied 
from 0–8% and were found to be a common 
problem for inpatients globally.6 The clinical 
features vary such as morbilliform, urticaria, 
contact dermatitis, Stevens-Johnson syndrome 
(SJS), toxic epidermal necrolysis (TEN), etc. 
ACDRs were found to be the most common 
form of adverse drug reaction in HIV patients. 
It was reported that drug hypersensitivity 
occurs a hundred times more frequent in 
HIV patients compared to HIV-negative 
individuals.7 Stevens-Johnson syndrome is a 
severe and rare skin disorder characterized 
by painful blister lesions that widespread on 
the skin and mucous membranes. Incidence of 
SJS has been linked to the deterioration of the 
immune system found in HIV infection.7 These 
manifestation could affect patients’ adherence 
and outcomes to therapy, which eventually 
affect morbidity and mortality rate in HIV 
patients. This study aimed to describe the local 
prevalence, patients’ characteristics such as 
sex, age, and CD4 count also clinical features 
and drug causing ACDRs.
Methods
This study was conducted from September– 
November 2019 in Teratai Clinic Dr. Hasan 
Sadikin General Hospital Bandung using a 
retrospective cross-sectional approach as 
the study design. This study used secondary 
data, which were patients’ medical records 
as its instrument. The population of this 
study was HIV/AIDS patients undergoing 
ARV therapy in Teratai Clinic. Inclusion 
criteria were medical records of HIV patients 
diagnosed with ACDRs while undergoing ARV 
therapy from 2014–2018 in Teratai Clinic. The 
exclusion criteria were incomplete medical 
records. The sampling was total sampling. The 
total number of the case was 94 but only 90 
cases were evaluable. The research has been 
approved by the Research Ethics Committee of 
the Universitas Padjadjaran (835/UN6.KEP/
EC/2019).
This study was started by collecting data on 
HIV patients that were diagnosed with ACDRs 
in Teratai Clinic. The result was presented in 
percentage.
Results
This study found 94 cases from 2014–2018 
with the prevalence of 16.9%. ACDRs in HIV 
patients were found to be more prevalent in 
men (70%) compared to women (30%). The 
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Table 1 Characteristics of HIV Patients with ACDRs
Characteristics
HIV Patients with ACDRs (n=90)
n %
Age (years old)
     <20 2 2.2
     20–29 36 40
     30–39 35 38.9
     40–49 14 15.6
     50–59 3 3.3
Gender
     Male 63 70
     Female 27 30
History of Allergy
     Yes 6 6.7
     No 11 12.2
     Unknown 73 81.1
Note: ACDRs=adverse cutaneous drug reactions
Althea Medical Journal. 2020;7(4)
202     AMJ December 2020
cases were commonly found in age between 
20–39 years old (78.9%). The majority of 
the patients do not know their allergy status 
prior to the incident (81.1%). Only 6.7% of the 
patients have been diagnosed with the allergy 
before.
This study found that the most common 
clinical features of ACDRs were morbilliform 
and SJS (85.6% and 8.9% respectively). Half 
number of the patients (50%) found to be in 
the AIDS phase. Only 2 patients (2.2%) have a 
high number of CD4. Morbilliform was found 
in a wide range of populations with variable 
CD4 count. Other clinical features such as SJS, 
urticaria, and erythroderm primarily were 
found in individuals with low CD4 count.
Forty-eight patients (53.3%) have 
opportunistic infection. Opportunistic 
infections found in HIV patients were 
Candidiasis (41.7%), Tuberculosis (27%), 
Toxoplasmosis (16.7%), Syphilis (4.2%), and 
others (8.5%).
Cotrimoxazole has the highest number of 
case-related to ACDRs (27.8%). Efavirenz and 
Nevirapine were the most common cause of 
ACDRs found among the ARV group (26.7% 
and 14.5% respectively). Several drugs, 
consisting of a combination of antituberculosis, 
antiretroviral, and antibiotic groups, caused 
thirteen cases (14.5%). 
Discussions
This study found predominance in males 
aged between 20–39 years old. The number 
of male patients is 63 (70%) with an M/F sex 
ratio of 2.33. This observation is similar to 
several studies in Asia in China4 and Korea8 as 
well as a study in another part of Indonesia.9 
However, other studies show different results, 
for example, study in Cameroon, Central 
Africa10 found that 82.9% of HIV patients with 
drug eruptions were female. Similar to a study 
in South Africa that shows a high number of 
female patients.11 This difference is assumed 
to be caused by the demographic. In Indonesia, 
there was a higher number of male patients 
in the HIV-infected population.1 The relation 
between ACDRs and sex was assumed to be 
influenced by several factors such as body 
fat percentage, hormonal factor, and enzyme 
activities.12
This study found the majority of the patients 
were between 20–39 years old. This result is 
similar to previous studies that also showed a 
majority of the patients were in age between 
30–40 years old, which is reproductive age.4,8,9 
History of allergy was assumed to influence 
the incidence of ACDRs. A previous study has 
found there was the higher rate of allergic 
history in the drug eruption group compared 
Table 2 CD4 Count in HIV Patients with Adverse Cutaneous Drug Reactions and with 
Opportunistic Infection
CD4 Count (cell/mm3)
<200 200–499 ≥500 Total
Clinical Features
     Morbiliform 37 38 2 77(85.6)
     Stevens-Johnson Syndrome 6 2 0 8(8.9)
     Urticaria 1 3 0 4(4.4)
     Erythroderm 1 0 0 1(1.1)
     Total 45(50) 43(47.8) 2(2.2) 90
Opportunistic Infections
     Tuberculosis 9 4 13(27)
     Candidiasis 17 3 20(41.7)
     Toxoplasmosis 7 1 8(16.7)
     Syphilis 1 1 2(4.2)
     Others 3 2 5(10.4)
     Total 37(77) 11(23) 48
Note: CD4= cluster of differentiation 4
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to the control group, indicating a correlation 
between the two.4 Another study has shown 
there was no substantial correlation between 
sex and history of allergy to ACDRs in HIV 
patients.13 In this study, only 6.7% of people 
have an allergic history. This low number 
thought to be caused by the high number of 
patient that does not know their allergy status.
This study found half number of the patients 
(50%) was in the AIDS phase, characterized 
by low CD4 count. A study in South Africa 
revealed that there was a decreased number 
of CD4 in HIV patients with TEN.14 The exact 
mechanism of SJS and TEN was still not clearly 
understood. It has been linked to the depletion 
of skin-protective CD4 regulatory T cells that 
have an important role in maintaining the 
homeostasis of the skin. The loss of regulatory 
T cell leads to expansion of CD8 effect or T cell 
that could injure keratinocyte. The depletion 
of CD4 cell found in the HIV population thus 
increase the risk of developing severe ACDRs, 
such as SJS and TEN.14,15 The low number of CD4 
also associated with susceptibility to acquiring 
OIs.8,16 In this study, there were 77% of patients 
with a low count of CD4 accompanied with 
OIs. This is caused by the incapability of the 
host’s immune system to counter pathogens. 
This condition requires patients to take both 
ARV and OIs medications simultaneously. This 
could induce drug interactions that lead to 
ACDRs. 17
In this study, there were 48 cases (53.3%) 
that accompanied OIs. The most common OIs is 
candidiasis and tuberculosis (41.7% and 27% 
respectively), similar to find in Korea,8and in 
India.16 The high number of tuberculosis in 
this study could also be supported by the high 
incidence rate of tuberculosis in Indonesia.18
In this study, morbilliform and SJS were 
found to be the most common clinical features 
of ACDRs (85.6% and 8.9% respectively). A 
previous study in the same clinic in Teratai 
Clinic from 2005 until 2014 has shown similar 
results that morbilliform and SJS as the most 
common clinical features in ACDRs among 
HIV patients (89.7% and 8.7% respectively).12 
The previous study also found that 55% of the 
cases found within the group with low CD4 
count (<200 cell/mm3).12
In this study, the suspected drugs were 
predominant in non-nucleoside reverse 
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Table 3 Clinical Features in HIV Patient with ACDRs
Suspected drugs
Clinical features of ACDRs
Morbilliform Urticaria SJS Erythroderm Total 
NRTI
     Zidovudin 1 (1.3) 1 (12.5) 2 (2.2)
NNRTI
     Nevirapin 11 (14.3) 2 (25) 13 (14.5)
     Efavirenz 20 (26) 4 (100) 24 (26.7)
     Rilpivirine 1 (1.3) 1 (1.1)
     Antituberculosis 3 (3.9) 1 (100) 4 (4.4)
Antibiotic
     Cotrimoxazole 23 (29.8) 2 (25) 25 (27.8)
     Amoxicillin 1 (1.3) 1 (1.1)
     Clindamycin 1 (1.3) 1 (1.1)
Antifungal
     Fluconazole 3 (3.9) 1 (12.5) 4 (4.4)
Analgesic
     Acetaminophen 2 (2.6) 2 (2.2)
     Combination 11 (14.3) 2 (25) 13 (14.5)
Total 77 4 8 1 90
Note: ACDRs=adverse cutaneous drug reactions, NRTI=nucleoside reverse transcriptase inhibitor, NNRTI= Non-
nucleoside reverse transcriptase inhibitor, SJS= Stevens- Johnson syndrome
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transcriptase inhibitors (NNRTI) drugs and 
antibiotic drugs. Efavirenz and Nevirapin 
have the highest number of cases among 
NNRTI drugs, 26.7% and 14.5% respectively. 
Cotrimoxazole has the highest number as a 
suspected drug with 27.8%. Similar to the 
study in Jakarta17 Nevirapine is the most 
common drug to cause ACDRs, as common 
as 15% to 32%. Nevirapine has been used 
as the most common NNRTI drugs due to 
its cost-effectiveness, but often associated 
with adverse drug reactions that could affect 
cutaneous, hepatic, or systemic.19 This study 
found a lower number of cases associated with 
Nevirapine compared to Efavirenz. This result 
is assumed to be caused by the lessened use of 
Nevirapine due to its known inclination with 
adverse drug reactions. The exact mechanism 
of Nevirapine causing ACDRs is still not well 
understood. It is thought to be related to 
genetic factors, particularly HLA. A study found 
Nevirapine shares a common binding groove 
F pocket with HLA-C*04:01 which increased 
the risk of hypersensitivity reactions when 
exposed to Nevirapine.19
In this study, SJS as a severe form of 
ACDRs was found to be commonly caused by 
Cotrimoxazole (25%) and Nevirapine (25%). 
Again, similar to findings in Jakarta that the 
occurrence of Stevens-Johnson syndrome is 
higher in Nevirapine compared to Efavirenz.17 
Another study in Canada20 revealed that the 
incidence of SJS and/or TEN was 1–2 per 1000 
individuals in HIV patients. The incidence of 
SJS and/or TEN in HIV patients often linked to 
the increased risk of hypersensitivity reaction 
in HIV patients. It was reported that HIV 
patients are a hundred times more frequent 
to acquire drug hypersensitivity compared to 
HIV negative-individuals.7
The exact mechanism of increased risk 
of hypersensitivity reaction in HIV patients 
is still unclear. It primarily has been linked 
to dysregulation of the immune system. The 
continuous injury of HIV-infected cells and 
depletion of immunoregulatory cells induce 
immune response and release of cytokine. 
This leads to immune activation which is 
associated with increased production of IP-
10 and MIG, TNF-α, IL-6, IFN-α, and IL-10. 
Immune activation also increased levels 
of IFN-ɣ that induce an increase in drug 
presentation and leads to an increased risk of 
developing hypersensitivity reaction.15 Other 
factors such as changes in drug metabolism, 
oxidative stress, and genetic factors also have 
been associated.7,17
The limitation of this study is that the 
diagnosis presented on the data was not 
confirmed with a specific test which could 
identify the exact drug causing ACDRs.
In conclusion, CDRs are found to be common 
in HIV patients, with the prevalence of 16.9%. 
A high number of cases is found in a young 
adult males with low CD4. The most common 
clinical features of ACDRs are morbilliform 
and SJS. The most common drug ACDRs are 
Cotrimoxazole, Efavirenz, and Nevirapine.
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